Jeffrey W. Albers is CEO & President at Blueprint Medicines Corp (BPMC). They have made 44 open-market trades across 1 company since 2015, most recently 2026-08-07.
CIK 0001638474
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 44 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRE | SELL · 10b5-1 | 2026-08-07 | 2026-08-10 | $104.53 | $2.4M | +3.2% | -16.7% | — |
| KYMR | SELL · 10b5-1 | 2025-12-08 | 2025-12-08 | $89.76 | $898K | -12.2% | -15.5% | -6.3% |
| KYMR | SELL · 10b5-1 | 2025-10-13 | 2025-10-14 | $59.19 | $296K | +0.1% | +8.8% | +25.0% |
| KYMR | SELL · 10b5-1 | 2025-06-03 | 2025-06-03 | $49.00 | $311K | +7.4% | +2.4% | -7.0% |
| BPMC | SELL · 10b5-1 | 2025-05-27 | 2025-05-29 | $101.23 | $572K | +24.0% | +24.2% | N/A |
| BPMC | SELL · 10b5-1 | 2025-03-12 | 2025-03-14 | $87.80 | $659K | -0.2% | -9.2% | +41.1% |
| BPMC | SELL | 2025-03-05 | 2025-03-17 | $88.80 | $1.0M | -2.8% | -11.1% | +38.9% |
| BPMC | SELL · 10b5-1 | 2025-01-21 | 2025-01-23 | $109.39 | $2.5M | -1.2% | -19.4% | -25.2% |
| BPMC | SELL · 10b5-1 | 2025-01-13 | 2025-01-15 | $102.28 | $511K | +9.1% | -10.4% | -22.3% |
| BPMC | SELL · 10b5-1 | 2024-12-19 | 2024-12-20 | $89.37 | $2.2M | -1.5% | +24.8% | -1.4% |
| BPMC | SELL · 10b5-1 | 2024-11-07 | 2024-11-12 | $102.00 | $510K | -3.9% | -5.5% | +6.1% |
| SYRE | SELL · 10b5-1 | 2024-11-06 | 2024-11-08 | $36.76 | $246K | -29.2% | -31.0% | -38.6% |
| SYRE | SELL · 10b5-1 | 2024-10-25 | 2024-10-28 | $36.43 | $11K | +9.9% | -19.1% | -39.3% |
| BPMC | SELL · 10b5-1 | 2024-09-09 | 2024-09-11 | $85.57 | $3.4M | +4.0% | +2.6% | +10.2% |
| KYMR | SELL · 10b5-1 | 2024-08-26 | 2024-08-26 | $49.10 | $246K | -7.5% | +5.9% | -4.2% |
| BPMC | SELL · 10b5-1 | 2024-03-20 | 2024-03-22 | $87.09 | $3.8M | +3.5% | +3.4% | +20.1% |
| BPMC | SELL | 2024-03-07 | 2024-03-26 | $90.69 | $2.0M | +1.6% | +0.7% | +17.8% |
| KYMR | SELL · 10b5-1 | 2024-02-20 | 2024-02-21 | $39.05 | $366K | +7.0% | +2.3% | -11.3% |
| BPMC | SELL · 10b5-1 | 2024-01-25 | 2024-01-29 | $81.97 | $3.2M | -12.3% | +12.8% | +10.1% |
| KYMR | SELL · 10b5-1 | 2024-01-23 | 2024-01-23 | $30.05 | $301K | +4.6% | +28.5% | +9.0% |
| BPMC | SELL · 10b5-1 | 2023-12-11 | 2023-12-13 | $79.07 | $791K | +6.8% | -2.4% | +5.5% |
| BPMC | SELL | 2023-11-30 | 2023-12-04 | $70.55 | $353K | +16.4% | +23.2% | +26.1% |
| BPMC | SELL · 10b5-1 | 2023-11-24 | 2023-11-28 | $67.61 | $1.5M | +7.7% | +33.0% | +38.3% |
| BPMC | SELL · 10b5-1 | 2023-11-01 | 2023-11-03 | $60.15 | $924K | +6.5% | +21.6% | +33.6% |
| BPMC | SELL · 10b5-1 | 2023-09-27 | 2023-09-29 | $49.87 | $2.2M | +0.7% | +8.7% | +82.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.